# A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

> **NCT04109092** · PHASE1 · WITHDRAWN · sponsor: **Eisai Inc.**

## Conditions studied

- Urinary Bladder Neoplasms

## Interventions

- **DRUG:** E7766

## Key facts

- **NCT ID:** NCT04109092
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02-13
- **Primary completion:** 2022-09-29
- **Final completion:** 2022-09-29
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** There was no enrolment of participants.Unscheduled Clinical Study Closure - Eisai Network Company Decision, November 12, 2020.
- **Last updated:** 2020-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04109092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04109092, "A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04109092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*